Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgerynews2025-01-08T15:55:49+00:00January 8th, 2025|Medical Device News Magazine|
Number of FDA product adcomms last year returned to 2022 levelsnews2025-01-07T20:15:50+00:00January 7th, 2025|Endpoints News|
FDA sets an efficacy threshold for new weight loss drugsnews2025-01-07T19:29:24+00:00January 7th, 2025|Endpoints News|
Drugmakers cut list prices for some cancer, asthma and diabetes treatmentsnews2025-01-07T19:22:48+00:00January 7th, 2025|Endpoints News|
New FDA guidance on accelerated approvals, AI, clinical trialsnews2025-01-06T20:12:48+00:00January 6th, 2025|Endpoints News|
FDA drug approvals 2024: Rare diseases, schizophrenia and Alzheimer’snews2025-01-06T15:00:39+00:00January 6th, 2025|Endpoints News|
Florida car dealer joins insulin pricing fight against Eli Lilly, Sanofinews2025-01-03T19:28:08+00:00January 3rd, 2025|Endpoints News|
Novo petitions FDA over Victoza compounding as first generic wins approvalnews2025-01-03T18:06:06+00:00January 3rd, 2025|Endpoints News|
Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approvalnews2025-01-02T19:59:55+00:00January 2nd, 2025|Endpoints News|
FDA adcomm to review Novartis’ Fabhalta in ultra-rare kidney diseasenews2025-01-02T19:15:51+00:00January 2nd, 2025|Endpoints News|
